This week, we have a conversation with Catalym’s Eugen Leo about Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15.
Solid tumors are a big challenge. However, a new approach might provide the answer – tumor-activated Therapy. We discuss this with Seekyo Therapeutics’ CEO, Oury Chetboun